Review: CNS toxicity involving methylene blue: The exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity

Journal of Psychopharmacology

Volumn 25, Issue 3, 2011, Pages 429-436

  Ken Gillman, P ^a  

^a PsychoTropical Research   (Australia)

Author keywords

methylene blue; monoamine oxidase inhibitor; serotonin reuptake inhibitor; serotonin syndrome; serotonin toxicity

Indexed keywords

BROMPHENIRAMINE; CHLORPHENIRAMINE; CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; METHADONE; METHYLENE BLUE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PENTAZOCINE; PETHIDINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TRAMADOL; VENLAFAXINE;

AGITATION; ARTICLE; CASE REPORT; CLONUS; CONFUSION; DIAPHORESIS; DIARRHEA; DISEASE SEVERITY; HUMAN; HYPERREFLEXIA; INFORMATION RETRIEVAL; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MUSCLE HYPERTONIA; MYDRIASIS; NAUSEA; NERVOUSNESS; NEUROTOXICITY; OCULAR CLONUS; PRIORITY JOURNAL; PUBLICATION; RIGIDITY; SEROTONIN TOXICITY; SEROTONINERGIC SYSTEM; TEMPERATURE; TREMOR; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG INTERACTION; HOSPITALIZATION; METABOLISM; PATHOPHYSIOLOGY; REVIEW; SEROTONIN SYNDROME;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; METHYLENE BLUE; MONOAMINE OXIDASE INHIBITORS; SEROTONIN; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 79952127097     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109359098     Document Type: Article

References (63)

1. Aeschlimann C., Cerny T., Kupfer A. (1996) Inhibition of (mono)-amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 24: 1336-1339. (Pubitemid 26427170)
2. Bach KK, Lindsay FW, Berg LS, Howard RS (2004) Prolonged postoperative disorientation after methylene blue infusion during parathyroidectomy. Anesth Analg 99: 1573-1574. (Pubitemid 39407318)
3. Biswas PN, Wilton LV, Shakir SA (2003) The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13554 patients in England. J Psychopharmacol 17: 121-126. (Pubitemid 36373150)
4. Boyer EW, Shannon M. (2005) The serotonin syndrome. N Engl J Med 352: 1112-1120.
5. Burhenne J., Riedel KD, Rengelshausen J., et al. (2008) Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. J Chromatogr B Biomed Sci App 863: 273-282.
6. Del Duca D., Sheth SS, Clarke AE, Lachapelle KJ, Ergina PL (2009) Use of methylene blue for catecholamine-refractory vasoplegia from protamine and aprotinin. Ann Thorac Surg 87: 640-642.
7. Dudley NE (1971) Methylene blue for rapid identification of the parathyroids. Br Med J 3: 680-681.
8. Dunkley EJC, Isbister GK, Sibbritt D., Dawson AH, Whyte IM (2003) Hunter Serotonin Toxicity Criteria: a simple and accurate diagnostic decision rule for serotonin toxicity. Q J Med 96: 635-642. (Pubitemid 37063272)
9. Gillman PK (1998) Serotonin syndrome: history and risk. Fundam Clin Pharmacol 12: 482-491. (Pubitemid 29166491)
10. Gillman PK (1999) The serotonin syndrome and its treatment. J Psychopharmacol 13: 100-109. (Pubitemid 29141280)
11. Gillman PK (2003) Mirtazapine: unable to induce serotonin toxicity ? Clin Neuropharmacol 26: 288-289.
12. Gillman PK (2004) Mirtazapine: not a dual action antidepressant ? Aust NZ J Psychiatry 38: 266-267. (Pubitemid 38578585)
13. Gillman PK (2005 a) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95: 434-441. (Pubitemid 41418735)
14. Gillman PK (2005 b) Understanding toxidromes: serotonin toxicity: a commentary on Montanes-Rada et al. J Clin Psychopharmacol 25: 625-626. (Pubitemid 41669072)
15. Gillman PK (2006 a) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59: 1046-1051. (Pubitemid 43849654)
16. Gillman PK (2006 b) A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol 21: 117-125.
17. Gillman PK (2006 c) Extracting value from case reports: lessons from serotonin toxicity. Anaesthesia 61: 419-422.
18. Gillman PK (2006 d) Methylene blue implicated in potentially fatal serotonin toxicity. Anaesthesia 61: 1013-1014. (Pubitemid 44377475)
19. Gillman PK (2009) Triptans, serotonin agonists, and serotonin toxicity. Headache [Epub ahead of print]. Available at http://www.ncbi.nlm.nih.gov/pubmed/ 19925619?dopt=Citation (accessed November 17, 2009 ).
20. Han N., Bumpous JM, Goldstein RE, Fleming MM, Flynn MB (2007) Intra-operative parathyroid identification using methylene blue in parathyroid surgery. Am Surg 73: 820-823. (Pubitemid 351396601)
21. Isbister GK, Buckley NA (2005) The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 28: 205-214. (Pubitemid 41579617)
22. Isbister GK, Hackett LP (2003) Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. J Toxicol Clin Toxicol 41: 167-173. (Pubitemid 36520467)
23. Isbister GK, Whyte IM (2003) Adverse reactions to mirtazapine are unlikely to be serotonin toxicity. Clin Neuropharmacol 26: 287-288.
24. Isbister GK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 187: 361-365.
25. Isbister GK, Hackett LP, Dawson AH, Whyte IM, Smith AJ (2003) Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 56: 441-450. (Pubitemid 37188140)
26. Kartha SS, Chacko CE, Bumpous JM, Fleming M., Lentsch EJ, Flynn MB (2006) Toxic metabolic encephalopathy after parathyroidectomy with methylene blue localization. Otolaryngol Head Neck Surg 135: 765-768. (Pubitemid 44634869)
27. Khan MA, North AP, Chadwick DR (2007) Prolonged postoperative altered mental status after methylene blue infusion during parathyroidectomy: a case report and review of the literature. Ann R Coll Surg Engl 89: W9-11.
28. Khavandi A., Whitaker J., Gonna H. (2008) Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue. Med J Aust 189: 534-535.
29. LoVecchio F., Riley B., Pizon A., Brown M. (2008) Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. J Emerg Med 34: 77-78.
30. McRobb CM, Holt DW (2008) Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J Extra Corpor Technol 40: 206-214.
31. Majithia A., Stearns MP (2006) Methylene blue toxicity following infusion to localize parathyroid adenoma. J Laryngol Otol 120: 138-140. (Pubitemid 46825668)
32. Martindale SJ, Stedeford JC (2003) Neurological sequelae following methylene blue injection for parathyroidectomy. Anaesthesia 58: 1041-1042. (Pubitemid 37254208)
33. Mathew S., Linhartova L., Raghuraman G. (2006) Hyperpyrexia and prolonged postoperative disorientation following methylene blue infusion during parathyroidectomy. Anaesthesia 61: 580-583. (Pubitemid 43740713)
34. Mechan AO, Esteban B., O'Shea E., Elliott JM, Colado MI, Green AR (2002) The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135: 170-180. (Pubitemid 34102110)
35. Meissner PE, Mandi G., Coulibaly B., et al. (2006) Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J 5: 84.
36. Mhra (2008) Methylthioninium chloride (methylene blue). CNS toxicity with serotonergic drugs. Drug Safety Update 1: 5.
37. Mhra (2009) Methylthioninium chloride (methylene blue). update on CNS toxicity with serotonergic drugs. Drug Safety Update 2: 3.
38. Mihai R., Mitchell EW, Warwick J. (2007) Dose-response and postoperative confusion following methylene blue infusion during parathyroidectomy. Can J Anaesth 54: 79-81. (Pubitemid 46178794)
39. Naylor GJ, Smith AH, Connelly P. (1987) A controlled trial of methylene blue in severe depressive illness. Biol Psychiatry 22: 657-659. (Pubitemid 17069852)
40. Ng BK, Cameron AJ, Liang R., Rahman H. (2008) Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review: [Syndrome serotoninergique suite a une perfusion de bleu de methylene pendant une parathyroidectomie: presentation de cas et analyse bibliographique]. Can J Anaesth 55: 36-41.
41. Oz M., Lorke DE, Petroianu GA (2009) Methylene blue and Alzheimer's disease. Biochem Pharmacol: doi:10.1016/ j.bcp.2009.1004.1034.
42. Pollack G., Pollack A., Delfiner J., Fernandez J. (2009) Parathyroid surgery and methylene blue: a review with guidelines for safe intraoperative use. Laryngoscope 119: 1941-1946.
43. Ramsay RR, Dunford C., Gillman PK (2007) Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 152: 946-951. (Pubitemid 350100489)
44. Rosenbaum H. (2006) January 2006 Case of the Month. http://medical.mhaus. org/index.cfm/fuseaction/Content.Display/PagePK/CaseOfTheMonth2.cfm (accessed March 2009 )
45. Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479: 23-40. (Pubitemid 37377873)
46. Rowley M., Riutort K., Shapiro D., Casler J., Festic E., Freeman WD (2009) Methylene blue-associated serotonin syndrome: a 'green' encephalopathy after parathyroidectomy. Neurocrit Care 11: 88-93.
47. Schaper E., Farber E., Ebbecke M., Desel H. (2002) Suicide with mirtazapine -hardly possible. J Toxicol Clin Toxicol 40: 343-344.
48. Schwiebert C., Irving C., Gillman PK (2009) Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia 64: 924-924.
49. Shanmugam G., Kent B., Kirby S., Baskett R. (2008) Serotonin syndrome following cardiac surgery. Interact Cardiovasc Thorac Surg 7: 656-657.
50. Stanford BJ, Stanford SC (1999) Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 13: 313-317. (Pubitemid 29435800)
51. Stanford SC, Stanford BJ, Gillman PK (2009) Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol: doi:10.1177/ 0269881109105450).
52. Stawicki SP, Sims C., Sarani B., Grossman MD, Gracias VH (2008) Methylene blue and vasoplegia: who, when, and how? Mini Rev Med Chem 8: 472-490.
53. Sun-Edelstein C., Tepper SJ, Shapiro RE (2008) Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf 7: 587-596.
54. Sweet G., Standiford SB (2007) Methylene-blue-associated encephalopathy. J Am Coll Surg 204: 454-458. (Pubitemid 46283509)
55. Walter-Sack I., Rengelshausen J., Oberwittler H., et al. (2009) High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 65: 179-189.
56. Waring WS, Good AM, Bateman DN (2007) Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. Clin Toxicol (Phila) 45: 45-50.
57. Wegener G., Volke V., Rosenberg R. (2000) Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br J Pharmacol 130: 575-580. (Pubitemid 30332975)
58. Whyte IM (1999) Serotonin syndrome complicating the treatment of recurrent depression. Curr Ther 40: 6-7.
59. Whyte IM (2004) Serotonin toxicity (syndrome). In: Dart RC (ed.) Medical toxicology. Baltimore: Lippincott Williams & Wilkins, 103-106.
60. Whyte IM, Dawson AH (2002) Redefining the serotonin syndrome. J Toxicol Clin Toxicol 40: 668-669.
61. Whyte IM, Dawson AH, Buckley NA (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 96: 369-374. (Pubitemid 36592709)
62. Wischik CM, Bentham P., Wischik DJ, Seng KM (2008) Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers Dement 4: T167.
63. Zoungrana A., Coulibaly B., Sie A., et al. (2008) Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS ONE 3: e 1630.